The greatest harm of diabetes is various acute and chronic complications, especially diabetic retinopathy(DR), leading to extremely high rates of disability and blindness. Early screening, early diagnosis, and early treatment are the keys to maintaining vision in patients with DR. However, compared with the high prevalence of diabetes in China, the DR screening ability is relatively inadequate. To change this situation, deep learning(DL), a form of artificial intelligence (AI), might be a potential effective method to solve this dilemma.
The greatest harm of diabetes is various acute and chronic complications, especially DR, leading to extremely high rates of disability and blindness. However, if the fundus examination is carried out regularly in the early stages of onset, the risk of blindness can be significantly reduced. Therefore, early screening, early diagnosis, and early treatment are the keys to maintaining vision in patients with DR. However, compared with the high prevalence of diabetes in China, the DR screening ability is relatively inadequate. The Diabetic Retinopathy Screening and Prevention Program is a branch project of MMC. Its purpose is to carry out an efficient workflow for early detecting, timely managing of DR, and to establish a referral system for implementing treatment and the long-term follow-up of DR by means of DL. First, In order to improve its sensitivity and specificity, more participants are involved in other medical institutes besides MMCs, then we can effectively explore the prevalance of DR in China and helps to early screening, prevention, treatment and referal process of DR. Secend, we collect participants' serum, plasma,DNA, several medical stastistics and life styles to explore genetics, new biomarkers, risk factors of DR. Objective: 1. To validate the methodology and feasibility of DR screening using a DL based automated DR grading system in clinical practice. 2. To explore the prevalence of DR and subgroup identification, and fundus images analysis, etc. 3. To explore the genetics, new biomarkers, risk factors of DR. 4. To explore the methods of early screening, prevention, treatment and referal process of DR.
Study Type
OBSERVATIONAL
Enrollment
500,000
Ruijin hospital, Shanghai Jiao-Tong University School of Medicine
Shanghai, Shanghai Municipality, China
RECRUITINGShanghai Jiao-Tong University School of Medicine
Shanghai, China
RECRUITINGDiabetic retinopathy
diabetic retinopathy
Time frame: through study completion, up to 20 years
Referable diabetic retinopathy
Referable diabetic retinopathy
Time frame: through study completion, up to 20 years
Vision threatening diabetic retinopathy
Vision threatening diabetic retinopathy
Time frame: through study completion, up to 20 years
Diabetic macular edema
Diabetic macular edema
Time frame: through study completion, up to 20 years
HbA1c (%)
Time frame: through study completion, up to 20 years
Smoking history
Time frame: through study completion, up to 20 years
Alcohol intake
Time frame: through study completion, up to 20 years
Salt intake
Time frame: through study completion, up to 20 years
Vegetable and fruits intake
Time frame: through study completion, up to 20 years
Physical activity
Time frame: through study completion, up to 20 years
Blood pressures (mmHg)
Time frame: through study completion, up to 20 years
Lipids (mg/dl)
Time frame: through study completion, up to 20 years
Cardiolvascular diseases
Time frame: through study completion, up to 20 years
Body mass index (BMI)
Body weight (kg) and height (m) will be combined to report BMI in kg/m\^2
Time frame: through study completion, up to 20 years
Systolic blood pressure
Time frame: through study completion, up to 20 years
Diastolic blood pressure
Time frame: through study completion, up to 20 years
Visceral fat (cm^2)
Time frame: through study completion, up to 20 years
Fasting glucose (mmol/L)
Time frame: through study completion, up to 20 years
Postprandial glucose (mmol/L)
Time frame: through study completion, up to 20 years
Fasting serum C peptide (ug/L)
Time frame: through study completion, up to 20 years
Postprandial serum C peptide (ug/L)
Time frame: through study completion, up to 20 years
Fasting serum insuline (μIU/mL)
Time frame: through study completion, up to 20 years
Postprandial serum insuline (μIU/mL)
Time frame: through study completion, up to 20 years
Intimal medial thikness (mm)
Time frame: through study completion, up to 20 years
Pulse wave velocity (cm/s)
Time frame: through study completion, up to 20 years
Albumin-creatinine-ratio (mg/mmol)
Time frame: through study completion, up to 20 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.